Annexin Pharmaceuticals AB (publ)
www.annexinpharma.comAnnexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.
Read moreAnnexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.
Read moreCountry
City (Headquarters)
Stockholm
Industry
Employees
1-10
Founded
2014
Social
Employees statistics
View all employeesPotential Decision Makers
Board Member
Email ****** @****.comPhone (***) ****-****Chief Operating Officer
Email ****** @****.comPhone (***) ****-****Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Chief Financial Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(11)